Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
51 hedge funds and large institutions have $457M invested in Tourmaline Bio in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 9 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
31% more capital invested
Capital invested by funds: $349M → $457M (+$107M)
6% more funds holding
Funds holding: 48 → 51 (+3)
0.97% more ownership
Funds ownership: 6.26% → 7.22% (+0.97%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.82M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.42M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$4.03M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.26M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$8.19M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.65M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.04M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$848K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$642K |
TRML Hedge Fund Activity: Q4 2021 in Review
51 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q4 2021, worth a combined $457M — up 31% from $349M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TRML positions and 9 closed out — a net gain of 3 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $9.82M. The largest seller was Sectoral Asset Management, cutting an estimated $8.19M.
- 51 institutional investors held Tourmaline Bio (TRML) as of Q4 2021, up from 48 in Q3 2021.
- Funds reported $457M of Tourmaline Bio stock for Q4 2021, up 31% quarter-over-quarter.
- 12 funds opened new Tourmaline Bio positions in Q4 2021 and 9 closed out, a net change of +3 holders.
- The largest Tourmaline Bio buyer in Q4 2021 was BlackRock, an estimated $9.82M added.
- The largest Tourmaline Bio seller in Q4 2021 was Sectoral Asset Management, an estimated $8.19M sold.
Based on aggregated 13F filings for Q4 2021.